(NASDAQ: TARA) Protara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Protara Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast TARA's revenue for 2025 to be $712,413,170, with the lowest TARA revenue forecast at $712,413,170, and the highest TARA revenue forecast at $712,413,170. On average, 1 Wall Street analysts forecast TARA's revenue for 2026 to be $317,085,630, with the lowest TARA revenue forecast at $317,085,630, and the highest TARA revenue forecast at $317,085,630.
In 2027, TARA is forecast to generate $465,230,508 in revenue, with the lowest revenue forecast at $144,129,832 and the highest revenue forecast at $786,331,183.